

1. (Twice Amended) A method for evaluating the morphogenic activity of a candidate morphogenic protein or analog thereof, the method comprising the steps of:

- B¹
sub
C¹
- (a) creating, for purposes of the evaluation, a local defect site in a mammal accessible to progenitor cells,
 - (b) administering said candidate morphogenic protein or analog systemically to said mammal at a site distal from the local permissive defect site,
 - (c) measuring the ability of the candidate protein or analog to induce new tissue formation at said defect site, and
 - (d) comparing the ability of said candidate with the ability of a control to perform the same function.

3. (Twice Amended) A method for evaluating an optimal dosage of a candidate morphogenic protein or analog thereof, the method comprising the steps of:

- B²
sub
C²
- (a) creating, for purposes of the evaluation, a local defect site in a mammal accessible to progenitor cells,
 - (b) administering said candidate morphogenic protein or analog systemically to said mammal at a site distal from the local permissive defect site,
 - (c) measuring the ability of the candidate protein or analog to induce new tissue formation at said defect site, and
 - (d) comparing the ability of said candidate with the ability of a control to perform the same function.

23. (Amended) The method of claim 1 or claim 3 wherein said morphogenic protein is a morphogenically active amino acid sequence variant of a morphogen selected from the group consisting of: OP1, OP2, OP3, BMP2, BMP3, BMP4, BMP5, BMP6, BMP9, BMP-10, BMP-11, BMP-12, BMP-15, BMP-3b, DPP, Vgr, Vgr, 60A protein, GDF-1, GDF-3, GDF-5, GDF-6, GDF-7, GDF-8, GDF-9, GDF-10, and GDF-11.

B³
sub
C³